MW
1,815.1 g/mol
Purity
>99%
Metabolic
AOD-9604
hGH Fragment 176–191
Synthetic fragment of the C-terminus of human growth hormone (hGH 176–191), stabilized with an added tyrosine residue
$125
Per vial · Research use only · COA available
Compound Profile
| Appearance | Lyophilized white powder |
| Molecular Weight | 1,815.1 g/mol |
| Amino Acids | 16 |
| Dosage | 10 mg |
| Volume | 3 mL |
| Solubility | Bacteriostatic or sterile water |
| Purity | ≥98% (HPLC-UV-MS verified) |
| Storage | −20°C long-term · 4°C short-term · Protect from light |
Amino Acid Sequence
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
COA, sterility, endotoxin, and heavy metal test results available upon request.
For Research Use Only. This product is not for human consumption, clinical use, or veterinary use. Must be 21+ to purchase. Not evaluated or approved by the FDA for any therapeutic use. Introduction into humans or animals is strictly prohibited by law.
Overview
About AOD-9604
AOD-9604 is a modified fragment of the human growth hormone molecule corresponding to amino acids 176–191 — the region of hGH responsible for its fat-metabolizing (lipolytic) activity, isolated from the region responsible for hGH's growth-promoting effects. It has been studied specifically for effects on lipolysis and fat metabolism, including in published research into obesity and osteoarthritis-related cartilage regeneration.
Mechanism of Action
How It Works
Research indicates AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage) by mimicking the region of hGH that interacts with adipocyte receptors, without activating the full-length GH receptor pathway responsible for tissue growth or IGF-1 elevation. This separation is the basis for AOD-9604's distinct research profile compared to other GH-axis peptides — studies have not observed the IGF-1 elevation associated with full-length hGH administration.
Scientific Literature
Research Highlights
Lipolytic activity isolated from hGH's growth-promoting (IGF-1-linked) effects
No reported IGF-1 elevation in published studies — key distinguishing safety variable
Studied in obesity and body-composition research models
Published research into chondrocyte activity and cartilage regeneration (osteoarthritis models)
No reported adverse effect on blood glucose regulation in clinical trial data
Fragment-based design — targets adipocyte lipid metabolism specifically
Distinct mechanism among GH-axis peptides, used as a comparative research reference
Research Disclaimer: All research highlights are derived from published preclinical, in vitro, and animal studies. Results observed in laboratory models may not translate to human outcomes. Genfinite makes no claims regarding therapeutic efficacy. All products are sold strictly for scientific research purposes only.
Handling
Storage & Reconstitution
Dry Storage
Store lyophilized powder at −20°C, away from light and moisture. Do not open until ready to use. Shelf life is significantly extended by proper dry storage.
Reconstitution
Reconstitute using Bacteriostatic or sterile water. Add solvent slowly to the side of the vial and allow to dissolve gently. Do not shake vigorously.
Post-Reconstitution
Store reconstituted solution refrigerated at 4°C. Use within your laboratory's established timeframe. Do not refreeze after reconstitution.
